Roche announced that it has obtained 510(k) approval from the United States Food and Drug Administration (FDA) for its ultra-sensitive in-situ hybridisation (ISH) assay, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail. The assessment...
ProMIS Neurosciences Inc., a biotechnology company at the clinical stage aimed at creating precise therapies for neurodegenerative diseases, announced the start of its phase 1b clinical trial (PRECISE-AD) assessing its primary therapeutic...
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm, announced encouraging topline findings from an open-label, phase 2 study on congenital adrenal hyperplasia (CAH) using investigational atumelnant, a new, once-daily oral...
Cycle Pharmaceuticals, Inc. (Cycle) has announced the successful acquisition of Banner Life Sciences, LLC (Banner), which encompasses its BAFIERTAM® (monomethyl fumarate) product for treating relapsing forms of multiple sclerosis (MS) in adults...
Iconovo AB, a company specializing in inhalable medications created with unique inhalers and dry powder formulations, has partnered with Lonza, a healthcare development and manufacturing firm, to develop spray-dried formulations of an intranasal...
AI technology is set to greatly reduce research and development expenses in pharmaceuticals by streamlining drug discovery, enhancing clinical trials, and utilizing predictive data analytics, as per GlobalData survey. The leading data and...
Newron Pharmaceuticals S.p.A, a biopharmaceutical firm dedicated to creating innovative treatments for disorders of the central and peripheral nervous systems, along with Myung In Pharm Co. Ltd. (Myung In Pharm), the foremost CNS-focused...
CAGE Bio, Inc., a biotechnology firm in clinical development focusing on novel treatments for prevalent immuno-dermatological conditions, announced the start of a phase 2b dose-ranging study for its CGB-500 product. This topical JAK inhibitor...
Telix Pharmaceuticals Limited has announced that it has signed an asset purchase agreement with antibody engineering firm ImaginAb, Inc. (ImaginAb) to obtain a pipeline of next-generation therapeutic candidates, an innovative proprietary biologics...
Pharma lobby group Federation of Pharma Entrepreneurs (FOPE) has urged the government to extend the deadline for compliance with the revised Schedule M by two years. This comes as the government is nearing finalisation of a draft notification...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
